Related references
Note: Only part of the references are listed.Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
Bob T. Li et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Gefitinib as neoadinvant therapy for resectahle stage II-IIIA non-small cell lung cancer: A phase II study
Yang Zhang et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2021)
ROS1-dependent cancers - biology, diagnostics and therapeutics
Alexander Drilon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
Wen-Zhao Zhong et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial
Alessandro Leonetti et al.
CLINICAL LUNG CANCER (2021)
Phase III study of selpercatinib vs chemotherapy plus /- pembrolizumab in untreated RET positive non-small-cell lung cancer
Benjamin J. Solomon et al.
FUTURE ONCOLOGY (2021)
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
Rafal Dziadziuszko et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review
Heather Burnett et al.
PLOS ONE (2021)
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
Gregory J. Riely et al.
CANCER DISCOVERY (2021)
Why Not Adore ADAURA? - The Trial We Need vs the Trial We Got
Howard (Jack) West et al.
JAMA ONCOLOGY (2021)
Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC
David Ross Camidge
JOURNAL OF THORACIC ONCOLOGY (2021)
OA01.06 Randomised Phase 2 Study of Nivolumab (N) Versus Nivolumab and Ipilimumab (NI) Combination in EGFR Mutant NSCLC
G. Lai et al.
Journal of Thoracic Oncology (2021)
P03.02 Neoadjuvant Osimertinib with/without Chemotherapy vs Chemotherapy for EGFR Mutated Resectable NSCLC: NeoADAURA
M. Tsuboi et al.
Journal of Thoracic Oncology (2021)
Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer
J. K. Sabari et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
MA11.07 Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors
B.C. Cho et al.
Journal of Thoracic Oncology (2021)
99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation
G.J. Riely et al.
Journal of Thoracic Oncology (2021)
MA11.09 Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer
D. Tan et al.
Journal of Thoracic Oncology (2021)
Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC
Misako Nagasaka et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
The Future of Clinical Trial Design in Oncology
Anna Spreafico et al.
CANCER DISCOVERY (2021)
Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
Khi Pin Chua et al.
CLINICAL CANCER RESEARCH (2021)
Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry
Alexander Drilon et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer A Randomized Clinical Trial
Leora Horn et al.
JAMA ONCOLOGY (2021)
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis
Giorgia Guaitoli et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
Vanita Noronha et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
James P. Solomon et al.
MODERN PATHOLOGY (2020)
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
Yukio Hosomi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Lung Cancer 2020 Epidemiology, Etiology, and Prevention
Brett C. Bade et al.
CLINICS IN CHEST MEDICINE (2020)
Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials
Bishal Gyawali et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
Alexander Drilon et al.
LANCET ONCOLOGY (2020)
Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis
Aaron C. Tan et al.
LUNG CANCER (2020)
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Alexander Drilon et al.
NATURE MEDICINE (2020)
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
T. Mok et al.
ANNALS OF ONCOLOGY (2020)
A phase II study of Osimertinib for patients with radiotherapy-naive CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)
Kazushige Wakuda et al.
BMC CANCER (2020)
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
Junji Tsurutani et al.
Cancer Discovery (2020)
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
Michael A. Gillette et al.
CELL (2020)
Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression
Yi-Ju Chen et al.
CELL (2020)
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Osimertinib plus platinum/pemetrexed in newly-diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study
D. Planchard et al.
ANNALS OF ONCOLOGY (2020)
Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first- line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)
D. W. Miles et al.
ANNALS OF ONCOLOGY (2020)
Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361
A. Alva et al.
ANNALS OF ONCOLOGY (2020)
The National Lung Matrix Trial of personalized therapy in lung cancer
Gary Middleton et al.
NATURE (2020)
Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC
Aaron C. Tan et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
Juergen Wolf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms t o targeted therapy
Kenichi Suda et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer
Jessica J. Lin et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study
Liwen Xiong et al.
ONCOLOGIST (2019)
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
A. J. Schoenfeld et al.
ANNALS OF ONCOLOGY (2019)
113OEntrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001
L Paz-Ares et al.
ANNALS OF ONCOLOGY (2019)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer
Kurtis D. Davies et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Neuregulin 1 Fusion-Positive NSCLC
Misako Nagasaka et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study
Caicun Zhou et al.
LANCET RESPIRATORY MEDICINE (2019)
ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
C. Marchio et al.
ANNALS OF ONCOLOGY (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
T Yau et al.
ANNALS OF ONCOLOGY (2019)
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer
H. Yoshioka et al.
ANNALS OF ONCOLOGY (2019)
LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042
R S Herbst et al.
ANNALS OF ONCOLOGY (2019)
Comparison of treatment effect from randomised controlled phase II trials and subsequent phase III trials using identical regimens in the same treatment setting
Fei Liang et al.
EUROPEAN JOURNAL OF CANCER (2019)
A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer
J. Rotow et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Molecular Testing Strategies for Pulmonary Adenocarcinoma An Optimal Approach With Cost Analysis
Lester J. Layfield et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
Management of Brain Metastases in Non-Small-Cell Lung Cancer
Vinicius Ernani et al.
JOURNAL OF ONCOLOGY PRACTICE (2019)
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology
Brian P. Hobbs et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2019)
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kazuhiko Nakagawa et al.
LANCET ONCOLOGY (2019)
Improving outcomes for brain metastases in EGFR mutated NSCLC
Jennifer W. Carlisle et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Simon Vyse et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer
Benjamin J. Solomon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations
Tony S. Mok et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Neal I. Lindeman et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Wen-Zhao Zhong et al.
LANCET ONCOLOGY (2018)
Higher Lung Cancer Incidence in Young Women Than Young Men in the United States
Ahmedin Jemal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma A Systematic Review and Meta-analysis
Chee Khoon Lee et al.
JAMA ONCOLOGY (2018)
Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment
J. Remon et al.
FRONTIERS IN ONCOLOGY (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK plus ) non-small-cell lung cancer: CNS efficacy results from the ALEX study
S. Gadgeel et al.
ANNALS OF ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
Thanyanan Reungwetwattana et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations
Jennifer Le-Rademacher et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials
Ariadna Tibau et al.
JAMA ONCOLOGY (2018)
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard et al.
JAMA ONCOLOGY (2018)
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J. Solomon et al.
LANCET ONCOLOGY (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement
Sun Min Lim et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria et al.
LANCET (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2017)
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Alexander Drilon et al.
Nature Reviews Clinical Oncology (2017)
Integrating liquid biopsies into the management of cancer
Giulia Siravegna et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Emmet J. Jordan et al.
CANCER DISCOVERY (2017)
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L. Paz-Ares et al.
ANNALS OF ONCOLOGY (2017)
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Peter Ballard et al.
CLINICAL CANCER RESEARCH (2016)
Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography
Daniel S. W. Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer
Vassiliki Papadimitrakopoulou et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Clinician Perspectives on Current Issues in Lung Cancer Drug Development
Saiama N. Waciar et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park et al.
LANCET ONCOLOGY (2016)
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Icotinib versus vinorelbine/platinum as adjuvant therapy in stage II-IIIA non-small cell lung cancer with EGFR-mutations: A multicenter, randomized, positive controlled, phase 3, indication-expanding study (EVIDENCE, CCTC-1501).
Jianxing He et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
C. Zhou et al.
ANNALS OF ONCOLOGY (2015)
ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer
Ramaswamy Govindan et al.
CLINICAL CANCER RESEARCH (2015)
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
Alexander Drilon et al.
CLINICAL CANCER RESEARCH (2015)
Innovative Clinical Trials: The LUNG-MAP Study
C. E. Steuer et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status
Wenzhao Zhong et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
James C-H Yang et al.
LANCET ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
Tatsushi Kodama et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma
Ji-Youn Han et al.
LUNG CANCER (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
A. Inoue et al.
ANNALS OF ONCOLOGY (2013)
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
S. Dearden et al.
ANNALS OF ONCOLOGY (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Comparison of Targeted Next-Generation Sequencing (NGS) and Real-Time PCR in the Detection of EGFR, KRAS, and BRAF Mutations on Formalin-Fixed, Paraffin-Embedded Tumor Material of Non-Small Cell Lung Carcinoma-Superiority of NGS
Katja Tuononen et al.
GENES CHROMOSOMES & CANCER (2013)
Tumor Response and Toxicity of Neoadjuvant Erlotinib in Patients With Early-Stage Non-Small-Cell Lung Cancer
Eva E. Schaake et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Role of randomized phase III trials in an era of effective targeted therapies
Manish R. Sharma et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Accelerated Approval of Oncology Products: The Food and Drug Administration Experience
John R. Johnson et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Edward S. Kim et al.
CANCER DISCOVERY (2011)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Phase II Study of Preoperative Gefitinib in Clinical Stage I Non-Small-Cell Lung Cancer
Humberto Lara-Guerra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
A. F. Gazdar
ONCOGENE (2009)
Lung cancer in never smokers - a different disease
Sophie Sun et al.
NATURE REVIEWS CANCER (2007)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system
JS Barnholtz-Sloan et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma
LJ Schouten et al.
CANCER (2002)
Share Paper
